<DOC>
	<DOCNO>NCT00018278</DOCNO>
	<brief_summary>The main purpose study determine electrophysiological effect cholinergic therapy ( cholinesterase inhibitor transdermal nicotine ) Alzheimer disease . The attempt locate electrophysiological marker predictor cognitive clinical treatment response .</brief_summary>
	<brief_title>Electrophysiologic Measures Treatment Response Alzheimer Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Patients diagnose mild moderate probable Alzheimer 's disease ( minimental state exam score 1527 ) , normal control ( age generally 6085 ) . Subjects must either plan start daily cholinesterase therapy ( e.g . Aricept , Exelon ) willing try transdermal nicotine patch two 8 hour period .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2004</verification_date>
</DOC>